Lower serum chromogranin B level is associated with type 1 diabetes and with type 2 diabetes patients with intensive conservative insulin treatment

Table 1 Anamnestic and laboratory measurement data of type 1 diabetes patients

Variable	Type 1 diabetes patients [n = 100]	Age and sex matched controls [n = 62]	p value
Age [years]	42.2 ± 13.4	44.1 ± 16.8	0.4443
Duration of diabetes [years]	17.3 ± 10.1	–	–
Chromogranin A [ng/mL]^a	61.64 ± 55.27	48.03 ± 19.99	0.0348
Chromogranin B [ng/mL]	89.39 ± 34.23	107.38 ± 59.77	0.0241
HbA_1C [%]	8.0 ± 1.7	–	–
HbA_1C [mmol/mol]	64.0 ± 18.6	–	–
White blood cell count [10⁹/L]	6.91 ± 1.77	7.08 ± 1.95	0.5894
Red blood cell count [10¹²/L]	4.88 ± 0.51	5.04 ± 0.56	0.0739
eGFR [mLmin⁻¹(1.73m²)⁻¹]	100.79 ± 18.65	100.26 ± 16.10	0.8483
Body mass index (BMI) [kg/m²]	25.6 ± 5.0	25.9 ± 5.3	0.7505
Sex (Female / Male)	50: 50	31: 31	1.0000
Hypertension	47	17	0.0140
Thyroid disease	31	4	0.0002
Gastroesophageal reflux disease	14	7	0.8104
Antacid therapy	6	5	0.7499

Values are expressed as mean ± standard deviation, unit of anamnestic data is the number of observations
eGFR Estimated glomerular filtration rate, HbA_1C Glycated hemoglobin
^aExcluding the measurement of study subjects, who had any condition leading to chromogranin A elevation [3, 4, 7]. Remaining number of observations was 91 and 56, respectively

ISSN: 1758-5996